Another meta-analysis by Wang et al. investigated the diagnostic performance of PET/CT using three different 18F-labeled radiotracers—18F-labeled choline, fluciclovine and PSMA—in patients with biochemical recurrent prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.